The Australian stock market has experienced a slight downturn, with the ASX200 dipping by 0.42% amid broad profit-taking following recent record highs, while investors keep a close watch on upcoming U.S. jobs data. In such fluctuating market conditions, identifying stocks that combine potential growth with financial stability becomes crucial for investors seeking opportunities. Penny stocks, though an older term, continue to offer intriguing possibilities in this regard; they often represent smaller or emerging companies that might surprise with their resilience and long-term potential.
Name | Share Price | Market Cap | Financial Health Rating |
Embark Early Education (ASX:EVO) | A$0.785 | A$144.03M | ★★★★☆☆ |
LaserBond (ASX:LBL) | A$0.58 | A$67.99M | ★★★★★★ |
SHAPE Australia (ASX:SHA) | A$2.84 | A$235.47M | ★★★★★★ |
Helloworld Travel (ASX:HLO) | A$2.01 | A$327.26M | ★★★★★★ |
Austin Engineering (ASX:ANG) | A$0.52 | A$322.48M | ★★★★★☆ |
MaxiPARTS (ASX:MXI) | A$1.75 | A$96.8M | ★★★★★★ |
Navigator Global Investments (ASX:NGI) | A$1.62 | A$793.93M | ★★★★★☆ |
Vita Life Sciences (ASX:VLS) | A$1.97 | A$110.79M | ★★★★★★ |
West African Resources (ASX:WAF) | A$1.63 | A$1.86B | ★★★★★★ |
Servcorp (ASX:SRV) | A$4.97 | A$490.37M | ★★★★☆☆ |
Click here to see the full list of 1,047 stocks from our ASX Penny Stocks screener.
Here we highlight a subset of our preferred stocks from the screener.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Little Green Pharma Ltd is involved in the cultivation, production, and distribution of medicinal cannabis products both in Australia and internationally, with a market cap of A$40.89 million.
Operations: The company's revenue is derived entirely from its pharmaceuticals segment, totaling A$28.88 million.
Market Cap: A$40.89M
Little Green Pharma Ltd, with a market cap of A$40.89 million, is unprofitable and has seen its losses increase by 10.2% annually over the past five years. Despite this, the company reported revenue growth to A$17.51 million for the half-year ending September 2024, up from A$12.8 million a year prior, though net loss widened to A$3.46 million from A$2.18 million. Its short-term assets surpass both short and long-term liabilities, and it maintains a cash runway exceeding three years due to positive free cash flow growth of 13.1% per year while trading below estimated fair value by 31%.
Simply Wall St Financial Health Rating: ★★★★★☆
Overview: OM Holdings Limited is an investment holding company involved in the mining, smelting, trading, and marketing of manganese ores and ferroalloys globally, with a market cap of A$263.69 million.
Operations: The company's revenue is primarily derived from its Smelting segment, which generated $441.70 million, and its Marketing and Trading segment, which contributed $631.02 million.
Market Cap: A$263.69M
OM Holdings, with a market cap of A$263.69 million, faces challenges from negative earnings growth of -68.8% over the past year and declining profit margins from 5.3% to 2%. Despite these issues, the company maintains satisfactory debt levels with a net debt to equity ratio of 34.5%, and its short-term assets exceed both short- and long-term liabilities, providing some financial stability. Recent sales figures show substantial production volumes in ferrosilicon and manganese alloys, aligning with maintained production guidance for 2024 between 460,000 to 490,000 tonnes per annum. The stock trades significantly below estimated fair value by nearly 80%.
Simply Wall St Financial Health Rating: ★★★★★★
Overview: Platinum Investment Management Limited is a publicly owned hedge fund sponsor with a market cap of A$594.08 million.
Operations: The company's revenue is primarily derived from Funds Management, contributing A$178.63 million, with an additional A$6.35 million from Investments and Other activities.
Market Cap: A$594.08M
Platinum Investment Management, with a market cap of A$594.08 million, is currently under M&A speculation involving Regal Partners and other firms. Despite trading at a discount to its estimated fair value, the company faces challenges such as declining earnings growth and reduced profit margins from 37.3% to 24.3%. The firm benefits from strong short-term asset coverage over liabilities and no debt burden, but its dividend yield of 7.55% is not well supported by earnings. The management team is experienced; however, the board lacks tenure stability with an average tenure of only 1.9 years.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include ASX:LGP ASX:OMH and ASX:PTM.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.